SUBSCRIBE: Print / eNewsletter
Researchers looked at whether time to first distant recurrence of metastatic melanoma was linked to survival outcomes.
The Memorial Sloan Kettering Cancer Center expert discussed a study he designed to discover why and how melanoma metastasizes, at the 16th International Congress of the Society for Melanoma Research.
The MD Anderson Cancer Center expert discussed how researchers are using genetic alterations to drive specific therapies at the 16th International Congress of the Society for Melanoma Research.
Poulikos Poulikakos, PhD, discussed combining targeted therapy and immunotherapy for the treatment of patients with melanoma at the 16th International Congress of the Society for Melanoma Research.
Sancy Leachman, MD, PhD, discusses her outreach effort titled “War on Melanoma” at the 16th International Congress of the Society for Melanoma Research.
Domenico Mallardo, MD, Istituto Nazionale Tumori "Fondazione Pascale" in Naples, discusses results from his trial – designed to evaluate anti-CTLA4 agents in patients with melanoma who relapsed on treatment with ipilimumab (Yervoy), which was presented at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
BRAF and MEK inhibitors appear to have clinical activity in patients with metastatic melanoma with rare BRAF mutations.
Researchers report on the best pembrolizumab protocol for advanced melanoma.
A pooled analysis included extended-survival data from COMBI-d and COMBI-v trials, both of which included treatment-naïve patients with unresectable or metastatic melanoma who were randomized to receive either dabrafenib plus trametinib or BRAF inhibitor monotherapy.
The new recommendations will help standardize neoadjuvant clinical trial methodology and develop a path for regulatory review and approval of neoadjuvant therapies in melanoma.
Melanoma of the skin is the 19th most common malignant neoplasm worldwide, with 287,723 new cases estimated for 2018 and metastatic melanoma accounting for 4% of all new cases. In recent years, the prognosis of this stage has undergone a dramatic transformation with the advent of immunotherapy and BRAF/MEK targeted therapy.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
